Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Sees Significant Growth in Short Interest

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) saw a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 457,500 shares, an increase of 90.3% from the December 31st total of 240,400 shares. Based on an average trading volume of 3,640,000 shares, the short-interest ratio is currently 0.1 days. Approximately 3.2% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

Separately, Maxim Group reiterated a “hold” rating on shares of Virpax Pharmaceuticals in a research report on Wednesday, October 9th.

Virpax Pharmaceuticals Trading Down 3.5 %

NASDAQ:VRPX opened at $0.31 on Friday. The company has a fifty day moving average of $0.36 and a 200 day moving average of $0.68. Virpax Pharmaceuticals has a 52 week low of $0.23 and a 52 week high of $5.48.

Hedge Funds Weigh In On Virpax Pharmaceuticals

A hedge fund recently bought a new stake in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC purchased a new stake in shares of Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned about 1.17% of Virpax Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 32.23% of the company’s stock.

Virpax Pharmaceuticals Company Profile

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.